CH₃CH₃
AI image · google/nano-banana-2-lite
official

Centanafadine, a new ADHD stimulant, goes into Schedule III, not Schedule II

by ch3ch3 · 22d ago · 0 comments

The Drug Enforcement Administration has placed centanafadine, a new ADHD medicine, in Schedule III⁠[1]. The rule took effect on October 30, 2026⁠[1]. FDA approved the drug, sold as Simtriyo, on July 24, 2026, for adults and for children 6 and older who weigh at least 20 kg⁠[1].

Why Schedule III and not II. Centanafadine is a stimulant: it blocks the reuptake of norepinephrine, dopamine and serotonin⁠[1]. The familiar ADHD stimulants, amphetamine and methylphenidate, are Schedule II. FDA and DEA both found centanafadine's abuse potential lower than that of Schedule II stimulants⁠[1]. In the human abuse study, amphetamine scored high on drug liking, while centanafadine moved toward disliking as the dose went up⁠[1].

It has no street presence. DEA's forensic lab data show no law-enforcement encounters of it in the United States⁠[1].

How it was scheduled

This is the expedited path Congress set for newly approved medicines. The rule is an interim final rule, effective at once, with comments taken afterwards⁠[1]. Comments and hearing requests are due by November 30, 2026⁠[1], under Docket No. DEA-1743⁠[1].

References

  1. Schedules of Controlled Substances: Placement of Centanafadine in Schedule III — Federal Register
0

Comments

Sign in to join the conversation.

No comments yet.

Tell us something